Filter by Published Year
July 21, 2021 | Nature

Gun violence is surging — researchers finally have the money to ask why

With historically high levels of new funding, US gun-violence research is starting to find its footing.

Read More
July 19, 2021 | Vox

The harrowing new reality for Alzheimer’s patients

Alzheimer’s patients and families live in a cloud of uncertainty. It’s about to get worse.

Read More
July 16, 2021

Dr. Beidas Advocates for Implementation Research and Mental Health Services in Congressional Briefing

Dr. Rinad Beidas was invited by the Friends of the National Institute of Mental Health (NIMH) coalition to participate in a congressional briefing to share information about mental health services and implementation research this July.

Read More
July 14, 2021 | Bloomberg Businessweek

One Health-Care Company’s Audacious Plan to Lower Costs—and Still Turn a Profit

Oak Street says frequent checkups, meetings with social workers, and free rides can keep patients out of hospitals.

Read More
July 13, 2021 | The New York Times

Top Tennessee Vaccine Official Says She Was Fired Over Shots for Teens

Michelle Fiscus, that state’s immunization leader, was only the latest state public health official to depart amid the pandemic.

Read More
July 9, 2021 | STAT

FDA calls for federal investigation into its controversial Alzheimer’s drug approval

The head of the FDA has called for a wide-ranging federal investigation into the approval of Biogen’s treatment for Alzheimer’s disease just one month after a decision that sparked the ire of lawmakers, doctors, and public health advocates.

Read More
July 8, 2021 | The New York Times

In Reversal, F.D.A. Calls for Limits on Who Gets Alzheimer’s Drug

Under fire for approving a questionable drug for all Alzheimer’s patients, the Food and Drug Administration greatly narrowed its previous recommendation and is now suggesting that only those with mild memory or thinking problems should receive it.

Read More
July 6, 2021 | STAT

Is the Alzheimer’s Association really pushing Biogen to lower its new drug’s price — or is it lip service?

The Alzheimer’s Association stunned Washington last month when it urged Biogen to lower the price of its new Alzheimer’s drug — an extremely rare rebuke on drug pricing from a patient advocacy group, most of which normally sidestep the topic.

Read More
July 3, 2021 | WHYY

Racial differences in COVID mortality rates linked to unequal hospital quality, Penn study shows

Black, Hispanic, and Asian American communities are more likely to contract the coronavirus, to be hospitalized because of the virus, and to have an increased risk of death from the virus when compared to their white counterparts.

Read More
June 24, 2021 | Vox

The new Alzheimer’s drug is the first of its kind. Will it be the last?

The FDA’s controversial approval of a Biogen drug for Alzheimer’s disease could blunt future R&D, experts warn.

Read More
June 17, 2021 | KHN

Device Makers Have Funneled Billions to Orthopedic Surgeons Who Use Their Products

Medical industry payments to orthopedists and neurosurgeons who operate on the spine have risen sharply, despite government accusations that some of these transactions may violate federal anti-kickback laws, drive up health care spending and put patients at risk of serious harm, a KHN investigation has found.

Read More
June 17, 2021 | CNN

Supreme Court dismisses challenge to Affordable Care Act, leaving it in place

The Supreme Court dismissed a challenge to the Affordable Care Act on Thursday in a decision that will leave the law intact and save health care coverage for millions of Americans.

Read More
June 15, 2021

Dr. Venkataramani Wins Milbank Quarterly Early Career Award in Population Health

Congratulations to Atheendar Venkataramani, MD, PhD, for receiving the 2021 Milbank Quarterly Early Career Award from the Interdisciplinary Association for Population Health Science.

Read More
June 9, 2021

Philadelphia Launches Philly Vax Sweepstakes

Members of our department helped Philadelphia launch the Philly Vax Sweepstakes, an incentive program to help boost COVID-19 vaccination rates among Philadelphia residents.

Read More
June 7, 2021 | Philadelphia Inquirer

Penn dementia expert on newly approved Alzheimer’s drug: ‘The data aren’t strong enough’

Well before the FDA approved aducanumab, the first new Alzheimer’s drug since 2003, many dementia experts were lining up to criticize the monoclonal antibody. Jason Karlawish, co-director of the Penn Memory Center, was among them.

Read More
May 30, 2021 | STAT

If the FDA approves Biogen’s Alzheimer’s treatment, I won’t prescribe it

From Jason Karlawish: Colleagues of mine in the Alzheimer’s sphere are also reluctant about approving aducanumab. Why? Biogen hasn’t made a convincing case for it.

Read More
May 28, 2021 | MedpageToday

Drug to Delay T1D Gets Tepid Endorsement by FDA Advisors

Teplizumab got a reticent thumbs-up from FDA advisors for an indication in delaying progression of at-risk patients to clinical type 1 diabetes (T1D).

Read More
May 24, 2021 | 6 ABC

Changing patterns and behaviors to improve mental health

As the world inches past the pandemic and things open up more, many people have vowed to make changes in their life, to get healthier, make a career change, or to create new social connections.

Read More
May 20, 2021 | The Philadelphia Inquirer

University of Pennsylvania Health System makes rare move to require COVID-19 vaccines for employees

The University of Pennsylvania Health System wants “to set an example for those who remain hesitant” by requiring employees to be vaccinated against COVID-19 by Sept 1.

Read More
May 19, 2021 | Healio

Outreach modality linked to HCV screening rates

More patients underwent hepatitis C virus screening when there was a reduced effort in attaining a laboratory order compared with patients who had to request screening on their own, according to research published in BMJ.

Read More

Loading tweets...